Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Translational Medicine

Background:

• Cancer immunotherapy represents a significant advancement in treatment, with numerous approaches in development or clinical trials.
• Preclinical animal models often fail to accurately represent human physiology, leading to challenges in translating findings to clinical settings.
• Species-specific immune system differences complicate the transfer of knowledge from preclinical to clinical studies.

Purpose of the Study:

• To review the history and implementation of tumor xenograft mouse models in cancer drug development.
• To discuss the progress, opportunities, and limitations of various humanized mouse models for preclinical cancer research.
• To highlight the importance of humanized models in overcoming species-specific barriers in immunotherapy research.

Main Methods:

• Review of existing literature on tumor xenograft mouse models, including humanized variants.
• Analysis of the application of these models in preclinical testing of cancer therapeutics.
• Discussion of methods for incorporating human immune components into mouse models, such as co-transplantation of peripheral blood mononuclear cells or hematopoietic stem cells.

Main Results:

• Human tumor cell line-based and patient-derived xenografts in immunocompromised mice are valuable for testing cytotoxic and targeted agents.
• These conventional xenograft models lack a human immune system component, limiting their predictive power for immunotherapy.
• Co-transplantation of human cells successfully introduces a human immune system counterpart, enhancing model relevance.

Conclusions:

• Humanized mouse models are essential for improving the preclinical evaluation of cancer immunotherapies.
• These models offer a more physiologically relevant platform for predicting treatment efficacy and overcoming translational challenges.
• Continued development and application of humanized models are critical for advancing personalized cancer therapy and drug development.